Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Amedisys Inc is a medical care facilities business based in the US. Amedisys shares (AMED) are listed on the NASDAQ and all prices are listed in US Dollars. Amedisys employs 21,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $110.82 |
|---|---|
| 52-week range | $101.61 - $276.21 |
| 50-day moving average | $118.92 |
| 200-day moving average | $146.70 |
| Wall St. target price | $161.00 |
| PE ratio | 18.0783 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $6.13 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $110.82 from 2022-07-01
| 1 week (2022-06-28) | 1.01% |
|---|---|
| 1 month (2022-06-03) | -3.85% |
| 3 months (2022-04-04) | -35.03% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -58.13% |
|---|---|
| 2 years (2020-07-02) | -45.71% |
| 3 years (2019-07-05) | 122.01 |
| 5 years (2017-07-05) | 76.24% |
Valuing Amedisys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amedisys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amedisys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Amedisys shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amedisys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4805. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amedisys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amedisys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $265.8 million.
The EBITDA is a measure of a Amedisys's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.2 billion |
|---|---|
| Operating margin TTM | 10.55% |
| Gross profit TTM | $993.8 million |
| Return on assets TTM | 8.42% |
| Return on equity TTM | 21.17% |
| Profit margin | 8.59% |
| Book value | $29.69 |
| Market capitalisation | $3.6 billion |
TTM: trailing 12 months
We're not expecting Amedisys to pay a dividend over the next 12 months.
Amedisys's shares were split on a 4:3 basis on 4 December 2006. So if you had owned 3 shares the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Amedisys shares – just the quantity. However, indirectly, the new 25% lower share price could have impacted the market appetite for Amedisys shares which in turn could have impacted Amedisys's share price.
Over the last 12 months, Amedisys's shares have ranged in value from as little as $101.61 up to $276.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amedisys's is 0.8779. This would suggest that Amedisys's shares are less volatile than average (for this exchange).
Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
